Adolor Corp (ADLR) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2007

Exhibit 99.1

FOR IMMEDIATE RELEASE

ADOLOR CORPORATION REPORTS

YEAR END 2007 FINANCIAL RESULTS

— Delta Program Update Provided —

EXTON, PA, February 29, 2008

2007 Financial Results

For the twelve months ended December 31, 2007, the company reported a net loss of $48.4 million or $(1.05) per basic and diluted share, compared to a net loss of $69.7 million, or $(1.56) per basic and diluted share for the same period in 2006. For the three month period ended December 31, 2007, the company reported a net loss of $10.1 million or $(0.22) per basic and diluted share, compared to a net loss of $18.4 million or $(0.40) per basic and diluted share in the three months ended December 31, 2006.

“We enter 2008 with two strong lead development programs, increasing momentum in discovery research, and a solid financial foundation,” said Michael R. Dougherty, president and chief executive officer of Adolor Corporation. “With our PDUFA date for Entereg on May 10, 2008, we await the FDA’s completion of its review of our NDA for postoperative ileus. We look ahead to realizing our objective of making this important new product available to patients in the near future.”

“A highlight of the fourth quarter of 2007 was our collaboration with Pfizer Inc for the Delta Program,” continued Dougherty. “Pfizer shares our vision for this program, the development of an entirely new class of opioid receptor agonists, and our joint efforts are now well underway. Finally, we are increasingly enthusiastic about our early discovery and research programs, and believe our efforts here will lead to the identification of new development candidates for our growing pipeline.”